Retrophin Announces Agreement to Acquire Orphan Technologies

Agreement adds OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria

Read more:
Retrophin Announces Agreement to Acquire Orphan Technologies

Related Posts